SREBF1 and diabetes mellitus: Moreover, DM triggers renal steatosis and lipotoxicity by inhibiting PPARα and PPARγ lipolytic [8,9,33,34], whilst increasing SREBP-1 lipogenic molecules [10,11], which then provoke chronic renal inflammation by augmenting renal TNF-α, IL-1β, and IL-6 levels, and reducing the potent anti-inflammatory cytokine, IL-10 [12,13].